All corrections
x.com/asparagoid/status/2028670382857670854
1 correction found
1
Claim
GLP-1s like Ozempic, Tirzapeptide and Retatutride
Correction
Two of the drug names in this list are misspelled. The correct names are **tirzepatide** (not “Tirzapeptide”) and **retatrutide** (not “Retatutride”).
Full reasoning
Why this is incorrect
The post lists “Tirzapeptide” and “Retatutride” as if those are the drug names. However, authoritative references use the spellings tirzepatide and retatrutide.
- Tirzepatide is the active ingredient in Mounjaro (and also Zepbound). The FDA-approved label explicitly names MOUNJARO® (tirzepatide).
- Retatrutide (spelled with an a after “ret-”, i.e., reta-) is the investigational molecule name used by the American Diabetes Association in its press release summarizing phase 2 trial data.
Because the post’s drug names don’t match the established/official names, the claim (as written) is factually inaccurate.
2 sources
- MOUNJARO (tirzepatide) — FDA label (highlights of prescribing information)
The FDA label states: “MOUNJARO® (tirzepatide) Injection, for subcutaneous use.”
- American Diabetes Association press release: “Highlights Novel Agent Retatrutide…” (June 26, 2023)
The ADA press release describes “...an investigational... receptor agonist, retatrutide” and refers to “Retatrutide (LY3437943) ...”